@EllaFlemyng And indeed, once the tool to flag problematic studies is up and running, we’d be very happy to check the citations effect. I agree we are unlikely to see a strong effect, unless the assessments are given high visibility.
@sam_macaulay Run! My kids are still recovering from a seagulls gang attack - stealing our fish and chips on the Kent seaside. To add to the humiliation, teenagers started filming and the whole thing must be somewhere on Tick Tock.
…’The (sun) moustache is letting me down’
…’I am dreading the summer’
After my 2nd pregnancy, I started developing dark spots on my face.
#melasma is not dangerous but it can really impact on quality of life.
I built a website to raise awareness
https://t.co/WaTRCnyHtn
Left: Twitter “immunology via screenshot” with 1.7 million views and big claims.
Right, Nature article where the *actual scientist* author is bewildered that her own paper, “which didn’t show evidence immune damage” from acute Covid went viral on Twitter with opposite claim.
🤷♀️
@murat_kocaoglu_ Hi, I volunteer for a social mobility charity working with secondary schools in the UK - this would be a great session for their students, thanks for sharing! I also really like the idea of having an outreach page on an academic website.
📚 We are launching a new project at the intersection of entrepreneurship, careers and calling @stefgson @virgiliofailla
🗣️ We would like to speak to @churchofengland ordained pioneers
👇🏻 Information and recruitment link:
https://t.co/IlRMZRTk7x
Are there tractable ways to increase the speed at which we learn whether new drugs are safe and effective?
I really appreciated the opportunity to talk with @maureenmfarrell about Paradigm’s new, important efforts to streamline clinical trials.
https://t.co/I9SewFd64B
Nice @AndersonReview summary of my work on disclosure in the pharmaceutical industry👇
TLDR: in more competitive markets, firms are more likely to delay and withhold the results of their trials https://t.co/Yv8p8tHY0i
@sam_macaulay So interesting and not too dissimilar from evergreening e.g. finding a second indication for a drug close to the drug’s patent expiration?